The researches find that the The drug is the first new therapy approved for myleofibrosis in nearly a decade, Celgene said in a statement. Myleofibrosis causes blood-forming bone marrow to be replaced with fibrous scar tissue. Therefore This deprives patients of energy and makes them vulnerable to infection. Blood-forming cells move to the spleen, liver and other parts of the body, causing additinoal complications. Fedratinib targets a mutation called JAK2 that drives certain kinds of myelofibrosis.
Blood-forming bone marrow
In clinical trials, oncologists including UC San Diego’s Dr. Catriona Jamieson reported patient responses including complete remissions that no other drug delivered. But after Sanofi withdrew the drug from clinical testing in 2013, some patients who had thrived on it died. Others survived on alternatives. Since then, Jamieson and John Hood; who led early research on the drug, had searched for ways to bring it back. Fedratinib has an unusually complicated history.
It sprang out of research at San Diego’s TargeGen, was tested by Sanofi; then shelved because a few patients developed a dangerous brain inflammation, with one death. Were it not for Hood, that would have been the end. Jamieson said one of her first patients on the federatinib trial, Theresa Blanda, bounced back on the drug after being very seriously ill. Her symptoms included a hugely swollen liver and knee, filled with displaced blood-forming stem cells.
Dangerous brain inflammation
Blanda went on the clinical trial in 2008. But when the drug was put on hold five years later, supplies dried up. Blanda relapsed. “It looked like she may succumb to the disease,” Jamieson said. “So I called John and said, What are we going to do about this? And John said, Well, we’re going to have to acquire the drug.” Hood said he acted because it was the right thing to do. “When you have patients who are truly responding to a drug that you’re behind, who desperately need it, you do whatever you can to make sure they get it,” Hood said.
“That’s the moment people in this industry live for. If you don’t drop everything, you’re in the wrong industry.” “I quit my job, worked out a deal with Sanofi, the local San Diego VCs and a third party to fund it, and started a company.” The effort took longer than anticipated, in part because of the need to answer the safety concerns. But in 2017, Hood founded Impact Biomedicines to bring back fedratinib. Because Impact was purchased by Celgene in January 2018 for $1.1 billion upfront, plus milestones that could bring the total price to $7 billion.